Balancing toxicity and efficacy: learning from trials and treatment using antiresorptive therapy in prostate cancer.
Authors
Clarke, Noel WAffiliation
The Christie and Salford Royal Hospitals, Manchester, UK. Electronic address: noel.clarke@srft.nhs.uk.Issue Date
2013-07-26
Metadata
Show full item recordCitation
Balancing toxicity and efficacy: learning from trials and treatment using antiresorptive therapy in prostate cancer. 2013: Eur UrolJournal
European UrologyDOI
10.1016/j.eururo.2013.07.026PubMed ID
23948437Type
ArticleLanguage
enISSN
1873-7560ae974a485f413a2113503eed53cd6c53
10.1016/j.eururo.2013.07.026
Scopus Count
Collections
Related articles
- Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
- Authors: Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN, Galsky MD
- Issue date: 2014 Feb
- [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
- Authors: Kudlacek S, Puntus T
- Issue date: 2012 Sep
- [Inhibition of RANK ligand to treat bone metastases].
- Authors: Body JJ
- Issue date: 2013 Nov
- Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.
- Authors: Fusco V, Galassi C, Berruti A, Ciuffreda L, Ortega C, Ciccone G, Angeli A, Bertetto O
- Issue date: 2011 Jun 10
- Denosumab an option for patients with bone metastasis from breast cancer.
- Authors: Barton MK
- Issue date: 2011 May-Jun